YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation
Status:
Unknown status
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess the feasibility of evaluating YSPSL for the amelioration of
ischemia reperfusion injury following liver transplantation by administering YSPSL into the
liver graft directly ex vivo via the portal vein and to the recipient intravenously prior to
reperfusion. Recently, P-selectin expression has been associated in liver grafts with
prolonged cold storage times and rejection. By examining biomarkers of IRI including
P-selectin by immunohistochemistry and/or quantitative PCR, liver histology and hepatic blood
flow using established techniques, the goal of this study is to evaluate the feasibility of
using these modalities for future studies of safety and efficacy.